Bowen Acquisition CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Bowen Acquisition Corp is seeking shareholder approval to extend its deadline for completing a business combination from June 14, 2026, to December 31, 2026, to allow more time to finalize its merger with Shenzhen Qianzhi BioTechnology Co. Ltd.
NASDAQ
Bowen Acquisition Corp. seeks shareholder approval to extend its business combination deadline to June 14, 2026, to finalize its merger with Shenzhen Qianzhi BioTechnology Co. Ltd.
NASDAQ
Bowen Acquisition Corp (BOWN) is calling an Extraordinary General Meeting on July 11, 2025, to seek shareholder approval for an extension of its business combination deadline from July 14, 2025, to December 14, 2025, as it continues efforts to consummate its previously approved merger with Shenzhen Qianzhi BioTechnology Co. Ltd.
NASDAQ
Bowen Acquisition Corp is seeking shareholder approval to extend the deadline for completing its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. by up to three months, from April 14, 2025, to July 14, 2025.
NASDAQ
DEF 14A: Bowen Acquisition Corp Seeks Extension to Complete Business Combination with Qianzhi BioTechnology
Bowen Acquisition Corp is seeking shareholder approval to extend the deadline for completing its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. from January 14, 2025, to as late as April 14, 2025.